Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 14.92B | 14.20B | 13.31B | 12.63B | 11.48B | 11.08B |
Gross Profit | 11.71B | 13.70B | 3.44B | 12.19B | 11.06B | 10.72B |
EBITDA | 2.72B | 2.64B | 2.28B | 2.04B | 1.61B | 1.61B |
Net Income | 624.00M | 620.00M | 455.00M | 366.00M | 237.00M | 359.00M |
Balance Sheet | ||||||
Total Assets | 21.34B | 18.48B | 17.89B | 17.88B | 16.67B | 14.72B |
Cash, Cash Equivalents and Short-Term Investments | 247.00M | 28.00M | 6.00M | 259.00M | 86.00M | 25.00M |
Total Debt | 13.68B | 11.05B | 10.74B | 10.96B | 9.89B | 8.40B |
Total Liabilities | 16.32B | 13.49B | 12.97B | 13.19B | 12.14B | 10.39B |
Stockholders Equity | 5.02B | 4.99B | 4.92B | 4.68B | 4.53B | 4.33B |
Cash Flow | ||||||
Free Cash Flow | 1.77B | 1.95B | 1.62B | 1.33B | 1.11B | 1.27B |
Operating Cash Flow | 1.91B | 2.07B | 1.71B | 1.44B | 1.21B | 1.39B |
Investing Cash Flow | -1.49B | -358.00M | -93.00M | -214.00M | -258.00M | -226.00M |
Financing Cash Flow | -213.00M | -1.69B | -1.88B | -1.04B | -882.00M | -1.18B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | 9.85B | 12.10 | 12.39% | 1.76% | 10.27% | 33.48% | |
72 Outperform | €10.51B | 17.84 | 12.76% | 1.66% | 8.38% | 21.07% | |
70 Neutral | 2.11B | 9.71 | 6.86% | 2.45% | 6.74% | 75.70% | |
65 Neutral | 10.31B | 18.37 | 10.97% | 1.75% | 5.75% | 48.97% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
Ambea AB is set to release its second quarter 2025 financial results on August 19th, with a subsequent telephone conference hosted by CEO Mark Jensen and CFO Benno Eliasson. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.
Ambea AB has announced changes in its number of shares and votes due to the exercise of warrants by senior executives and key employees, as well as the cancellation of 6,000,000 shares. This adjustment results in a total of 84,101,290 shares and votes, with a registered share capital of SEK 2,376,632.862076. These changes reflect Ambea’s ongoing financial restructuring efforts and could impact its market positioning and shareholder value.
Ambea AB’s Annual General Meeting approved several key proposals, including a dividend of SEK 2.20 per share, re-election of board members, and authorization for share repurchase and issuance. The meeting also noted the failure to pass a long-term incentive program for executives, highlighting strategic decisions impacting the company’s governance and financial strategies.
Ambea AB reported a 5% increase in net sales for the first quarter of 2025, driven by organic growth and strategic acquisitions, including the entry into the Finnish market through the acquisition of Validia. This expansion is expected to enhance Ambea’s Nordic growth and strengthen its position in the healthcare sector, particularly in residential care and support services for people with disabilities.